Navrogen
Navrogen is dedicated to developing innovative therapeutic agents and diagnostic tools to overcome immunosuppressive mechanisms in Humoral Immuno-Oncology (HIO). Their mission is to translate clinical knowledge into innovation by targeting tumor-produced HIO factors that suppress humoral immune responses, thereby improving cancer treatment outcomes.
Industries
Nr. of Employees
small (1-50)
Navrogen
1837 University Cir. Science Center Room 218 Cheyney PA 19319
Products
Mesothelin-targeting antibody-drug conjugate for mesothelin-expressing solid tumors
A next-generation ADC designed to kill mesothelin-expressing tumor cells with payload selection and screening to retain efficacy in the presence of humoral immunosuppressive factors.
Next-generation anti-CD20 antibody with reduced susceptibility to humoral immunosuppression
An engineered anti-CD20 antibody with modifications to prevent functional suppression by tumor-produced humoral factors, aimed at improving cytotoxic activity against CD20-positive lymphomas.
Small-molecule CD16/Fc receptor activator to restore NK cell activity
A small-molecule compound identified from a natural product library that binds the CD16/Fc receptor to activate NK cells and restore cytotoxicity in the presence of humoral immunosuppressive factors.
De-immunized CD25-targeting immunotoxin for regulatory T cell depletion
A de-immunized immunotoxin that targets CD25 to selectively deplete regulatory T cells in the tumor microenvironment, intended to reduce local immune suppression and enable effector responses.
HIO-antagonist biologics and refractory bispecifics
Biologic agents and bispecific antibodies engineered to antagonize humoral immunosuppressive factors or resist their inhibitory effects.
Mesothelin-targeting antibody-drug conjugate for mesothelin-expressing solid tumors
A next-generation ADC designed to kill mesothelin-expressing tumor cells with payload selection and screening to retain efficacy in the presence of humoral immunosuppressive factors.
Next-generation anti-CD20 antibody with reduced susceptibility to humoral immunosuppression
An engineered anti-CD20 antibody with modifications to prevent functional suppression by tumor-produced humoral factors, aimed at improving cytotoxic activity against CD20-positive lymphomas.
Small-molecule CD16/Fc receptor activator to restore NK cell activity
A small-molecule compound identified from a natural product library that binds the CD16/Fc receptor to activate NK cells and restore cytotoxicity in the presence of humoral immunosuppressive factors.
De-immunized CD25-targeting immunotoxin for regulatory T cell depletion
A de-immunized immunotoxin that targets CD25 to selectively deplete regulatory T cells in the tumor microenvironment, intended to reduce local immune suppression and enable effector responses.
HIO-antagonist biologics and refractory bispecifics
Biologic agents and bispecific antibodies engineered to antagonize humoral immunosuppressive factors or resist their inhibitory effects.
Services
Collaborative research to discover and optimize antibody, bispecific, ADC and small-molecule candidates using proprietary HIO screening and lead optimization workflows.
Development of assays to detect tumor-produced humoral immunosuppression factors for use in patient stratification and therapeutic decision support.
Collaborative research to discover and optimize antibody, bispecific, ADC and small-molecule candidates using proprietary HIO screening and lead optimization workflows.
Development of assays to detect tumor-produced humoral immunosuppression factors for use in patient stratification and therapeutic decision support.
Expertise Areas
- Humoral immuno-oncology
- Antibody engineering and optimization
- Antibody-drug conjugate (ADC) development
- Bispecific antibody development
Key Technologies
- Antibody engineering (epitope modification/block removal)
- Antibody-drug conjugates (ADC)
- Bispecific antibody platforms
- De-immunized immunotoxins
News & Updates
The article describes the negative impact that the Humoral Immuno-Oncology factor CA125 has on rituximab, obinutuzumab and tafasitamab, as well as T-cell engager antibodies, like mosunetuzumab and glofitamab.
The article describes new criteria for monoclonal antibody and antibody-drug conjugate development to treat cancers over-expressing the humoral immunosuppressive oncology (HIO) factor ICAM-1.
The article describes the negative impact that the Humoral Immuno-Oncology factor CA125 has on rituximab, obinutuzumab and tafasitamab, as well as T-cell engager antibodies, like mosunetuzumab and glofitamab.
The article describes new criteria for monoclonal antibody and antibody-drug conjugate development to treat cancers over-expressing the humoral immunosuppressive oncology (HIO) factor ICAM-1.